Every material Form 8-K Tyra Biosciences, Inc. has filed with the SEC since August 04, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
On September 14, 2026, Tyra Biosciences agreed to sell 9,079,000 shares of common stock and pre-funded warrants for 9,078,529 shares, with gross proceeds expected to be approximately $400.0 million before underwriting discounts and offering expenses. The offering is expected to close on September 15, 2026, and the company plans to use the net proceeds, together with existing cash, to advance its dabogratinib 3x3 development strategy, support preclinical and discovery programs, and fund working capital and general corporate purposes. Issuing these shares and warrants will dilute existing shareholders.
Offering of 9,079,000 common shares at $22.03 per share, plus pre-funded warrants for 9,078,529 shares at $22.029 per warrant
Underwriters agreed to buy the shares at $20.7082 per share; gross proceeds expected to be approximately $400.0 million
Closing expected September 15, 2026; proceeds targeted at dabogratinib 3x3 in LG-UTUC, IR NMIBC and achondroplasia
Tyra Biosciences reported initial Phase 2 SURF302 results for oral dabogratinib in FGFR3-altered low-grade intermediate-risk non-muscle invasive bladder cancer, as of an August 31, 2026 data cutoff. The company selected 60 mg once daily as the potential dose for a planned registrational adjuvant program, with a registrational study expected to start in 2027, subject to health authority feedback. Results are early, based on 26 evaluable participants, and the company notes they may change with further follow-up.
SURF302 3-month overall response rate was 79% (11/14) at 60 mg once daily and 67% (8/12) at 50 mg once daily
Grade 3 treatment-emergent adverse events occurred in 14% (3 of 22) at 60 mg and 9% (2 of 22) at 50 mg; no Grade 4 or 5 events were reported
The company plans to meet health authorities on Phase 3 design and dose selection and expects to start a registrational adjuvant study in 2027
Company estimates an IR NMIBC market opportunity of greater than $5 billion, based on third-party market research and assumptions
Tyra Biosciences reported a second-quarter 2026 net loss of $45.6 million, up from $28.1 million a year earlier, as research and development expenses rose to $39.2 million from $24.3 million. The company had $353.9 million in cash, cash equivalents and marketable securities at June 30, 2026, which it said should allow it to execute its plans into the second half of 2028. The filing also reports an amended at-the-market sales agreement with TD Securities (USA) LLC that allows sales of up to an additional $250.0 million of common stock.
Q2 2026 net loss was $45.6 million, or $0.69 per share, versus $28.1 million, or $0.47 per share, in Q2 2025.
R&D expenses were $39.2 million versus $24.3 million; G&A expenses were $9.8 million versus $7.1 million.
Cash, cash equivalents and marketable securities were $353.9 million at June 30, 2026; runway extends into the second half of 2028.
An amended ATM sales agreement with TD Securities (USA) LLC permits sales of up to an additional $250.0 million of common stock.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Tyra Biosciences, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →